CANCER TREATMENT BY TARGETING PROTEINS OR INTERACTIONS OF EPHRINB-RGS3-KIF20A-SEPT7 AXIS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 18, 2024
app pub date -
Apr 6, 2022
filing date -
Apr 8, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A method of treating cancer in a subject by targeting at least one of KIF20A, SEPT7, RGS3 and EphrinB or disrupting protein-protein interaction in the EPHRINB-RGS3-KIF20A-SEPT7 axis. The method entails administering to the subject an RNA-based inhibitor such as an siRNA, shRNA, or miRNA or a peptide inhibitor which targets at least one of KIF20A, SEPT7, RGS3 and EphrinB or blocks the binding of KID20A to RGS3 and/or SEPT7 or the binding of EphrinB and RGS3.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully